A new test provides a quicker way to assess the effects of medications for Alzheimer’s disease.

A new test provides a quicker way to assess the effects of medications for Alzheimer’s disease, using stable isotope labeling to measure amyloid-beta protein levels in cerebrospinal fluid. Reasearch was conducted by Randall Bateman, M.D., of Washington University in St. Louis and reported online in the Annals of NeurologyRead the full article >>